Skip to content
DataLookout
Menu

DETECSEPSNCT07942272

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Proportion of patients with optimized care pathway
Timeframe: 24 hours after inclusion

Secondary (18)

Death rate
Cumulative incidence of direct ICU admission
Cumulative incidence of secondary ICU admission
Proportion of patients with cognitive, psychological, or physical sequelae
Proportion of patients requiring renal, respiratory, or cardiovascular support
Show 13 moreShow less
Time to discharge to home
Time to resume previous social and professional activities
Quality of life - EQ-5D-5L
Quality of life - SF36
Cost of strategies and care pathways
Proportion of cases for which the combined diagnostic protocol is applied as intended
Proportion of test results available below a meaningful clinical duration to allow for patient management.
Proportion of appropriate integration of tests results within clinical workflow
Proportion of avoided hospitalization among patients receiving the intervention
Evolution of the proportion of eligible patients included over time
Environmental impact of study-related procedures
Life cycle analyse (LCA)
LCA comparison of the two clinical strategies

Arms and interventions

NEWS2 and H3.1-guided diagnostic and management strategyExperimental

Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol. Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below : * If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation. * If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required. * In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

Usual careOther

Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

Other: Plasma H3.1 concentration, NEWS2 score

Sites

5 sites in 1 country